425 related articles for article (PubMed ID: 35436808)
21. MR Fingerprinting and ADC Mapping for Characterization of Lesions in the Transition Zone of the Prostate Gland.
Panda A; Obmann VC; Lo WC; Margevicius S; Jiang Y; Schluchter M; Patel IJ; Nakamoto D; Badve C; Griswold MA; Jaeger I; Ponsky LE; Gulani V
Radiology; 2019 Sep; 292(3):685-694. PubMed ID: 31335285
[TBL] [Abstract][Full Text] [Related]
22. [Discussion of correlation between histogram analysis of quantitative diffusion weighted imaging and Gleason score of prostate cancer].
Wen R; Zhao WL; Wei CG; Gu YF; Li MJ; Zhang YY; Shen JK
Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(11):823-828. PubMed ID: 30893724
[No Abstract] [Full Text] [Related]
23. Biexponential apparent diffusion coefficients values in the prostate: comparison among normal tissue, prostate cancer, benign prostatic hyperplasia and prostatitis.
Liu X; Peng W; Zhou L; Wang H
Korean J Radiol; 2013; 14(2):222-32. PubMed ID: 23483254
[TBL] [Abstract][Full Text] [Related]
24. Probing structure of normal and malignant prostate tissue before and after radiation therapy with luminal water fraction and diffusion-weighted MRI.
Carlin D; Orton MR; Collins D; deSouza NM
J Magn Reson Imaging; 2019 Aug; 50(2):619-627. PubMed ID: 30589150
[TBL] [Abstract][Full Text] [Related]
25. Detectability of low and intermediate or high risk prostate cancer with combined T2-weighted and diffusion-weighted MRI.
Doo KW; Sung DJ; Park BJ; Kim MJ; Cho SB; Oh YW; Ko YH; Yang KS
Eur Radiol; 2012 Aug; 22(8):1812-9. PubMed ID: 22466514
[TBL] [Abstract][Full Text] [Related]
26. Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer.
Gupta RT; Kauffman CR; Garcia-Reyes K; Palmeri ML; Madden JF; Polascik TJ; Rosenkrantz AB
AJR Am J Roentgenol; 2015 Aug; 205(2):331-6. PubMed ID: 26204283
[TBL] [Abstract][Full Text] [Related]
27. Apparent Diffusion Coefficient (ADC) Ratio Versus Conventional ADC for Detecting Clinically Significant Prostate Cancer With 3-T MRI.
Bajgiran AM; Mirak SA; Sung K; Sisk AE; Reiter RE; Raman SS
AJR Am J Roentgenol; 2019 Sep; 213(3):W134-W142. PubMed ID: 31216201
[No Abstract] [Full Text] [Related]
28. Comparison of T2(*) mapping with diffusion-weighted imaging in the characterization of low-grade vs intermediate-grade and high-grade prostate cancer.
Wu LM; Zhao ZZ; Chen XX; Lu Q; Suo ST; Liu Q; Hu J; Haccke EM; Xu JR
Br J Radiol; 2016 Jul; 89(1063):20151076. PubMed ID: 27089897
[TBL] [Abstract][Full Text] [Related]
29. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of prostate cancer lesions in the Transition Zone by diffusion-weighted MRI.
Bao J; Wang X; Hu C; Hou J; Dong F; Guo L
Eur J Radiol Open; 2017; 4():123-128. PubMed ID: 29034282
[TBL] [Abstract][Full Text] [Related]
31. Histogram analysis of MR quantitative parameters: are they correlated with prognostic factors in prostate cancer?
Chen Y; Meng T; Cao W; Zhang W; Ling J; Wen Z; Qian L; Guo Y; Lin J; Wang H
Abdom Radiol (NY); 2024 May; 49(5):1534-1544. PubMed ID: 38546826
[TBL] [Abstract][Full Text] [Related]
32. "Textural analysis of multiparametric MRI detects transition zone prostate cancer".
Sidhu HS; Benigno S; Ganeshan B; Dikaios N; Johnston EW; Allen C; Kirkham A; Groves AM; Ahmed HU; Emberton M; Taylor SA; Halligan S; Punwani S
Eur Radiol; 2017 Jun; 27(6):2348-2358. PubMed ID: 27620864
[TBL] [Abstract][Full Text] [Related]
33. Revisiting quantitative multi-parametric MRI of benign prostatic hyperplasia and its differentiation from transition zone cancer.
Chatterjee A; Gallan AJ; He D; Fan X; Mustafi D; Yousuf A; Antic T; Karczmar GS; Oto A
Abdom Radiol (NY); 2019 Jun; 44(6):2233-2243. PubMed ID: 30955071
[TBL] [Abstract][Full Text] [Related]
34. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: histopathological validation using magnetic resonance-guided biopsy specimens.
Hoeks CM; Vos EK; Bomers JG; Barentsz JO; Hulsbergen-van de Kaa CA; Scheenen TW
Invest Radiol; 2013 Oct; 48(10):693-701. PubMed ID: 23614975
[TBL] [Abstract][Full Text] [Related]
35. [The value of synthetic MRI in differential diagnosis of benign and malignant breast lesions].
Che SN; Li J; Xue M; Song Y; Zhao LY; Guo N; Tian Y; Xie LZ; Zhao XM; Zhou CW
Zhonghua Zhong Liu Za Zhi; 2021 Aug; 43(8):872-877. PubMed ID: 34407594
[No Abstract] [Full Text] [Related]
36. [Combination of prostate imaging reporting and data system
with the apparent diffusion coefficient map for the diagnosis of peripheral zone prostate cancer].
Feng Z; Yan Z; Luo M; Liao Y; Rong P; Wang W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Mar; 44(3):277-284. PubMed ID: 30971520
[TBL] [Abstract][Full Text] [Related]
37. Diffusion Kurtosis Imaging Combined With DWI at 3-T MRI for Detection and Assessment of Aggressiveness of Prostate Cancer.
Wang X; Tu N; Qin T; Xing F; Wang P; Wu G
AJR Am J Roentgenol; 2018 Oct; 211(4):797-804. PubMed ID: 30085835
[TBL] [Abstract][Full Text] [Related]
38. Amide Proton Transfer Could Provide More Accurate Lesion Characterization in the Transition Zone of the Prostate.
Guo Z; Qin X; Mu R; Lv J; Meng Z; Zheng W; Zhuang Z; Zhu X
J Magn Reson Imaging; 2022 Nov; 56(5):1311-1319. PubMed ID: 35429190
[TBL] [Abstract][Full Text] [Related]
39. Prostate cancer: feasibility and preliminary experience of a diffusional kurtosis model for detection and assessment of aggressiveness of peripheral zone cancer.
Rosenkrantz AB; Sigmund EE; Johnson G; Babb JS; Mussi TC; Melamed J; Taneja SS; Lee VS; Jensen JH
Radiology; 2012 Jul; 264(1):126-35. PubMed ID: 22550312
[TBL] [Abstract][Full Text] [Related]
40. [Quantitative study of supraspinatus tendon injury grading based on synthetic magnetic resonance imaging].
Ni YB; Tian ZR; Yang JP; Wang YQ; Tian B; Gong R; Zhao W; Wang ZJ
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1603-1610. PubMed ID: 37248059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
